1-[4-(octahydro-pyrido[1,2-a]pyrazin-2-yl)-phenyl]-2-phenyl-1,2,3,4-tetrahydro-isoquinolin-6-ol

1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol is an experimental small molecule ligand developed by Wyeth Research (now Pfizer) for the study of the estrogen receptor alpha (ERα). Classified as a tetrahydroisoquinoline derivative, the compound serves as a selective estrogen receptor modulator (SERM) and has been primarily utilized in structural biology to elucidate the binding characteristics of the ERα ligand-binding domain. Its crystal structure in complex with the receptor is documented in the Protein Data Bank under entry 1xqc. While it demonstrates high affinity for the nuclear hormone receptor, it remains a research tool and has not progressed into clinical development for specific therapeutic indications.

Other names

DB03802DB-03802DB 038021XQ1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol